Cargando…

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline

Report of the first case, concerns and challenges of treatment of severe XDR-TB with both delamanid and bedaquiline http://ow.ly/WzeB3004Cmo

Detalles Bibliográficos
Autores principales:	Tadolini, Marina, Lingtsang, Rangjung Dolma, Tiberi, Simon, Enwerem, Martin, D'Ambrosio, Lia, Sadutshang, Tsetan Dorji, Centis, Rosella, Migliori, Giovanni Battista
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2016
Materias:	Agora
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007220/ https://www.ncbi.nlm.nih.gov/pubmed/27288039 http://dx.doi.org/10.1183/13993003.00637-2016

Ejemplares similares

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017)

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017)

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges
por: Tadolini, Marina, et al.
Publicado: (2016)

On tuberculosis and COVID-19 co-infection
por: Tadolini, Marina, et al.
Publicado: (2020)

Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study
por: Migliori, Giovanni Battista, et al.
Publicado: (2021)

Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion
por: Sotgiu, Giovanni, et al.
Publicado: (2015)

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
por: Wells, Charles D., et al.
Publicado: (2015)

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
por: Hafkin, Jeffrey, et al.
Publicado: (2017)

775. An Epidemiological Analysis of Patients With Multidrug-Resistant Tuberculosis Among Tibetan Refugees in India
por: Desel, Tenzin, et al.
Publicado: (2018)

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
por: Nimmo, Camus, et al.
Publicado: (2020)

A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium
por: D’Ambrosio, Lia, et al.
Publicado: (2017)

Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases
por: Tadolini, Marina, et al.
Publicado: (2020)

First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB
por: Lewis, Joseph M., et al.
Publicado: (2016)

Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Sotgiu, Giovanni, et al.
Publicado: (2016)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

Universal use of face masks for success against COVID-19: evidence and implications for prevention policies
por: Esposito, Susanna, et al.
Publicado: (2020)

Numbers needed to treat to prevent tuberculosis
por: Matteelli, Alberto, et al.
Publicado: (2015)

Global reporting on tuberculosis preventive treatment among contacts
por: Falzon, Dennis, et al.
Publicado: (2022)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: A case report and review of the literature
por: Esposito, Susanna, et al.
Publicado: (2016)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

Practices of therapeutic drug monitoring in tuberculosis: an international survey
por: Margineanu, Ioana, et al.
Publicado: (2022)

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
por: Nasiri, Mohammad Javad, et al.
Publicado: (2022)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
por: Hu, Minhui, et al.
Publicado: (2016)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?
por: Ndjeka, Norbert, et al.
Publicado: (2020)

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis
por: Akkerman, Onno W., et al.
Publicado: (2018)

Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!
por: Tiberi, Simon, et al.
Publicado: (2018)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020)

International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis
por: Migliori, Giovanni Battista, et al.
Publicado: (2019)

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
por: Guglielmetti, Lorenzo, et al.
Publicado: (2022)

Screening for tuberculosis among high-risk groups attending London emergency departments: a prospective observational study
por: Gupta, Rishi K., et al.
Publicado: (2021)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
por: Brigden, Grania, et al.
Publicado: (2015)

Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study
por: Franke, Molly F., et al.
Publicado: (2021)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
por: Millard, James, et al.
Publicado: (2023)

New anti-tuberculosis drugs and regimens: 2015 update
por: D'Ambrosio, Lia, et al.
Publicado: (2015)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Erratum: Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid: A Prospective Multicountry Study
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ogugj3a9saio9gsru6o07focuh